Dow Jones

42,129.73

0.01%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:AIM

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
19/09/2024	07:00	GlobeNewswire Inc.	AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
17/09/2024	11:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:AIM	AIM ImmunoTech Inc
12/09/2024	15:45	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:AIM	AIM ImmunoTech Inc
11/09/2024	16:40	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	AMEX:AIM	AIM ImmunoTech Inc
11/09/2024	08:00	GlobeNewswire Inc.	AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue	AMEX:AIM	AIM ImmunoTech Inc
20/08/2024	07:30	GlobeNewswire Inc.	AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	AMEX:AIM	AIM ImmunoTech Inc
16/08/2024	06:00	GlobeNewswire Inc.	AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
14/08/2024	16:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:AIM	AIM ImmunoTech Inc
13/08/2024	08:05	GlobeNewswire Inc.	AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
29/07/2024	08:15	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
25/07/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:AIM	AIM ImmunoTech Inc
25/07/2024	16:00	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:AIM	AIM ImmunoTech Inc
24/07/2024	07:50	GlobeNewswire Inc.	AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy	AMEX:AIM	AIM ImmunoTech Inc
11/07/2024	16:16	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	AMEX:AIM	AIM ImmunoTech Inc
10/06/2024	07:55	GlobeNewswire Inc.	AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference	AMEX:AIM	AIM ImmunoTech Inc
03/06/2024	08:15	GlobeNewswire Inc.	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series	AMEX:AIM	AIM ImmunoTech Inc
31/05/2024	07:30	GlobeNewswire Inc.	AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering	AMEX:AIM	AIM ImmunoTech Inc
20/05/2024	08:15	GlobeNewswire Inc.	AIM ImmunoTech to Participate in Two Upcoming Investor Conferences	AMEX:AIM	AIM ImmunoTech Inc
16/05/2024	06:30	GlobeNewswire Inc.	AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
09/05/2024	07:50	GlobeNewswire Inc.	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
06/05/2024	07:30	GlobeNewswire Inc.	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	AMEX:AIM	AIM ImmunoTech Inc
29/04/2024	07:55	GlobeNewswire Inc.	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
15/04/2024	07:55	GlobeNewswire Inc.	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	AMEX:AIM	AIM ImmunoTech Inc
10/04/2024	07:21	GlobeNewswire Inc.	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	AMEX:AIM	AIM ImmunoTech Inc
02/04/2024	06:30	GlobeNewswire Inc.	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
28/03/2024	07:05	GlobeNewswire Inc.	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	AMEX:AIM	AIM ImmunoTech Inc
26/03/2024	08:05	GlobeNewswire Inc.	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
25/03/2024	08:05	GlobeNewswire Inc.	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	AMEX:AIM	AIM ImmunoTech Inc
15/03/2024	07:45	GlobeNewswire Inc.	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	AMEX:AIM	AIM ImmunoTech Inc
07/03/2024	07:45	GlobeNewswire Inc.	AIM ImmunoTech Announces Launch of CEO Corner Platform	AMEX:AIM	AIM ImmunoTech Inc